Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeneGene-2 FIX Gene Therapy in Hemophilia B
2022-502844-11-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Jun 2023
- Modality
- Gene Therapies
- Countries
- 16
01
Overview
Phase 3, open-label, single-arm trial of fidanacogene elaparvovec in hemophilia B (HB), sponsored by Pfizer. Planned start Jun 2023; status: authorised.
02
Drugs
fidanacogene elaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2022-502844-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502844-11-00.